Observational studyFrontiers in endocrinology2026
Long-term glycemic outcomes of a diabetes management platform in a traditional Chinese medicine hospital: a real-world retrospective observational study.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sustained glycemic control in type 2 diabetes mellitus (T2DM) remains difficult in routine care. Long-term real-world evidence on diabetes management platforms in Traditional Chinese Medicine (TCM) hospitals is limited. Methods: We conducted a real-world retrospective observational study at Guangdong Provincial Hospital of Traditional Chinese Medicine. Adults with T2DM enrolled in a hospital-based chronic disease management platform between January 2017 and December 2018 were followed for up to 36 months. Primary outcomes were longitudinal changes in glycated hemoglobin (HbA1c) and HbA1c target attainment (<7.0%). Secondary outcomes included fasting blood glucose (FBG), postprandial blood glucose (PBG), body mass index (BMI), and self-reported lifestyle and self-management behaviors. Linear mixed-effects models and generalized estimating equations were used for longitudinal analyses. Results: A total of 546 patients were included. HbA1c decreased significantly over 36 months, and the proportion achieving HbA1c <7.0% increased from 30% at baseline to 49% at 12 months and remained around 45% at 24 and 36 months. Patients with baseline HbA1c >9.0% showed the greatest absolute reductions, whereas those with baseline HbA1c <7.0% generally maintained near-target levels. Clinically meaningful HbA1c reductions were common among participants with paired measurements, and sustained HbA1c target attainment was also observed across follow-up visits. In contrast, longitudinal changes in FBG were not significant, while reductions in PBG and BMI were modest. Improvements in lifestyle and self-management behaviors were limited. Conclusions: In this TCM hospital setting, platform-based chronic disease management was associated with sustained improvement in HbA1c over 3 years. Greater benefit was observed in patients with poor baseline glycemic control, although improvements in behavioral indicators and other metabolic measures were limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.